亚临床肥厚型心肌病的心脏重构:VANISH随机临床试验
VANISH试验探索缬沙坦对亚临床肌节型肥厚型心肌病(HCM)患者心脏重构的影响。
要点
- 缬沙坦未能显著延缓亚临床HCM患者的心脏重构进展。
- 2年内仅左房容积轻度增加,但18%患者进展为临床HCM。
- 基线左房容积指数和室间隔厚度较高与疾病进展相关。
核心结论
- 在探索性队列中,缬沙坦未能证明可减慢亚临床HCM的进展。
- 心脏重构标志物变化轻微,但近五分之一患者进展为临床HCM。
- 疾病转化与基线室间隔厚度和左房容积指数较高相关。
研究设计与样本
- 多中心、双盲、安慰剂对照随机临床试验(VANISH),2014年4月至2019年7月在4国17个中心开展,随访2年。
- 预设探索性队列纳入34例肌节变异携带者,有早期表型表现但无左室肥厚。
- 干预为安慰剂或缬沙坦(儿童<35kg 80mg/d,≥35kg 160mg/d;成人≥18岁 320mg/d)。
主要发现
- 9例(26%)左室壁厚度增加,其中6例(18%)进展为临床HCM。
临床怎么用
- 对于肌节变异携带者,应进行纵向随访以监测疾病进展。
- 缬沙坦不推荐用于延缓亚临床HCM进展。
- 基线左房容积指数和室间隔厚度较高者需更密切随访。
局限性
- 探索性队列样本量小(34例),所有参与者均为白人。
- 随访时间仅2年,可能不足以观察缬沙坦的长期效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression. OBJECTIVE: To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 years of follow-up. The prespecified exploratory VANISH cohort studied here included sarcomere variant carriers with subclinical HCM and early phenotypic manifestations (reduced E' velocity, electrocardiographic abnormalities, or an increased left ventricular [LV] wall thickness [LVWT] to cavity diameter ratio) but no LV hypertrophy (LVH). Data were analyzed between March and December 2022. INTERVENTIONS: Treatment with placebo or valsartan (80 mg/d for children weighing <35 kg, 160 mg/d for children weighing ≥35 kg, or 320 mg/d for adults aged ≥18 years). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite z score incorporating changes in 9 parameters of cardiac remodeling (LV cavity volume, LVWT, and LV mass; left atrial [LA] volume; E' velocity and S' velocity; and serum troponin and N-terminal prohormone of brain natriuretic peptide levels). RESULTS: This study included 34 participants, with a mean (SD) age of 16 (5) years (all were White). A total of 18 participants (8 female [44%] and 10 male [56%]) were randomized to valsartan and 16 (9 female [56%] and 7 male [44%]) were randomized to placebo. No statistically significant effects of valsartan on cardiac remodeling were detected (mean change in composite z score compared with placebo: -0.01 [95% CI, -0.29 to 0.26]; P = .92). Overall, 2-year phenotypic progression was modest, with only a mild increase in LA volume detected (increased by 3.5 mL/m2 [95% CI, 1.4-6.0 mL/m2]; P = .002). Nine participants (26%) had increased LVWT, including 6 (18%) who developed clinically overt HCM. Baseline LA volume index (LAVI; 35 vs 28 mL/m2; P = .01) and average interventricular septum thickness (8.5 vs 7.0 mm; P = .009) were higher in participants who developed HCM. CONCLUSIONS AND RELEVANCE: In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding of factors that drive disease penetrance and progression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01912534.
引用
- Vissing CR, Axelsson Raja A, Day SM, et al. Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37672268. doi:10.1001/jamacardio.2023.2808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。